APGE Apogee Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why APGE matters now
Apogee Therapeutics, Inc. (APGE) is a US stock in Healthcare. The latest InvestLog snapshot shows $133.25 with -0.22% on the session and $8.22B in market capitalization; recent performance reads 1-month +15.47% and YTD +19.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-74.1M, and EPS of $-1.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -4.2%.
The latest indexable market news headline is "Are AVB, LPRO, APGE, TMHC Obtaining Fair Deals for their Shareholders?" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $116.00; recent insider activity includes HENDERSON MICHAEL THOMAS filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
5.01
P/S
0.00
EV/EBITDA
-18.89
DCF Value
$2.09
FCF Yield
-4.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.6%
ROA
-21.2%
ROIC
-24.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-74.1M | $-1.06 |
| Q4 2025 | $0.00 | $-69.4M | $-1.03 |
| FY 2025 | $0.00 | $-255.8M | $-4.22 |
| Q3 2025 | $0.00 | $-65.0M | $-1.11 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$113.67
Target (Median)
$116.00
Target Range
$81.00 - $140.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.62
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.